Sermorelin
What it is
Sermorelin is an analogue of growth hormone-releasing hormone. It acts at the pituitary rather than supplying growth hormone directly. It is compounded and prescribed at provider discretion.
How it is used
Administered by subcutaneous injection, typically in the evening, on a protocol set by the prescriber. Duration and cycling vary considerably between protocols.
What a provider evaluates first
- Baseline IGF-1 and relevant pituitary function
- History of malignancy — a significant consideration with any growth-axis therapy
- Whether symptoms have another explanation that should be investigated first
Considerations and monitoring
- Compounded and not FDA-approved for this use
- Requires baseline and follow-up laboratory monitoring
- Injection-site reactions are commonly reported
Questions about sermorelin
Are peptides FDA-approved?
The peptides discussed in this category are not FDA-approved and have no approved indication. They are compounded preparations prescribed at the discretion of a licensed provider. There is no USP monograph for them, human clinical evidence is limited, and dosing protocols are not standardised between prescribers. Anyone presenting them as proven therapies is overstating what is known.
Part of Peptide Therapy.